Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.

Grünewald S, Politz O, Bender S, Héroult M, Lustig K, Thuss U, Kneip C, Kopitz C, Zopf D, Collin MP, Boemer U, Ince S, Ellinghaus P, Mumberg D, Hess-Stumpp H, Ziegelbauer K.

Int J Cancer. 2019 Sep 1;145(5):1346-1357. doi: 10.1002/ijc.32224. Epub 2019 Mar 13.

PMID:
30807645
2.

Discovery of Rogaratinib (BAY 1163877): a pan-FGFR Inhibitor.

Collin MP, Lobell M, Hübsch W, Brohm D, Schirok H, Jautelat R, Lustig K, Bömer U, Vöhringer V, Héroult M, Grünewald S, Hess-Stumpp H.

ChemMedChem. 2018 Mar 6;13(5):437-445. doi: 10.1002/cmdc.201700718. Epub 2018 Feb 16.

PMID:
29451369
3.

Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition.

Gelato KA, Schöckel L, Klingbeil O, Rückert T, Lesche R, Toedling J, Kalfon E, Héroult M, Lejeune P, Mönning U, Fernández-Montalván AE, Bäurle S, Siegel S, Haendler B.

Oncogene. 2018 Jan 25;37(4):512-521. doi: 10.1038/onc.2017.325. Epub 2017 Oct 9.

4.

Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells.

Basit F, van Oppen LM, Schöckel L, Bossenbroek HM, van Emst-de Vries SE, Hermeling JC, Grefte S, Kopitz C, Heroult M, Hgm Willems P, Koopman WJ.

Cell Death Dis. 2017 Mar 30;8(3):e2716. doi: 10.1038/cddis.2017.133.

5.

Neuropilin-1 mediates vascular permeability independently of vascular endothelial growth factor receptor-2 activation.

Roth L, Prahst C, Ruckdeschel T, Savant S, Weström S, Fantin A, Riedel M, Héroult M, Ruhrberg C, Augustin HG.

Sci Signal. 2016 Apr 26;9(425):ra42. doi: 10.1126/scisignal.aad3812.

PMID:
27117252
6.

Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth.

Schöckel L, Glasauer A, Basit F, Bitschar K, Truong H, Erdmann G, Algire C, Hägebarth A, Willems PH, Kopitz C, Koopman WJ, Héroult M.

Cancer Metab. 2015 Oct 20;3:11. doi: 10.1186/s40170-015-0138-0. eCollection 2015.

7.

Expression of the growth factor pleiotrophin and its receptor protein tyrosine phosphatase beta/zeta in the serum, cartilage and subchondral bone of patients with osteoarthritis.

Kaspiris A, Mikelis C, Heroult M, Khaldi L, Grivas TB, Kouvaras I, Dangas S, Vasiliadis E, Lioté F, Courty J, Papadimitriou E.

Joint Bone Spine. 2013 Jul;80(4):407-13. doi: 10.1016/j.jbspin.2012.10.024. Epub 2013 Jan 18.

PMID:
23333521
8.

EphB4 promotes site-specific metastatic tumor cell dissemination by interacting with endothelial cell-expressed ephrinB2.

Héroult M, Schaffner F, Pfaff D, Prahst C, Kirmse R, Kutschera S, Riedel M, Ludwig T, Vajkoczy P, Graeser R, Augustin HG.

Mol Cancer Res. 2010 Oct;8(10):1297-309. doi: 10.1158/1541-7786.MCR-09-0453. Epub 2010 Sep 13.

9.

Differential endothelial transcriptomics identifies semaphorin 3G as a vascular class 3 semaphorin.

Kutschera S, Weber H, Weick A, De Smet F, Genove G, Takemoto M, Prahst C, Riedel M, Mikelis C, Baulande S, Champseix C, Kummerer P, Conseiller E, Multon MC, Heroult M, Bicknell R, Carmeliet P, Betsholtz C, Augustin HG.

Arterioscler Thromb Vasc Biol. 2011 Jan;31(1):151-9. doi: 10.1161/ATVBAHA.110.215871. Epub 2010 Oct 14.

PMID:
20947821
10.

A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis.

Tremmel M, Matzke A, Albrecht I, Laib AM, Olaku V, Ballmer-Hofer K, Christofori G, Héroult M, Augustin HG, Ponta H, Orian-Rousseau V.

Blood. 2009 Dec 10;114(25):5236-44. doi: 10.1182/blood-2009-04-219204.

11.

Involvement of endothelial ephrin-B2 in adhesion and transmigration of EphB-receptor-expressing monocytes.

Pfaff D, Héroult M, Riedel M, Reiss Y, Kirmse R, Ludwig T, Korff T, Hecker M, Augustin HG.

J Cell Sci. 2008 Nov 15;121(Pt 22):3842-50. doi: 10.1242/jcs.030627. Epub 2008 Oct 28.

12.

The Wnt signaling regulator R-spondin 3 promotes angioblast and vascular development.

Kazanskaya O, Ohkawara B, Heroult M, Wu W, Maltry N, Augustin HG, Niehrs C.

Development. 2008 Nov;135(22):3655-64. doi: 10.1242/dev.027284. Epub 2008 Oct 8.

13.

Neuropilin-1-VEGFR-2 complexing requires the PDZ-binding domain of neuropilin-1.

Prahst C, Héroult M, Lanahan AA, Uziel N, Kessler O, Shraga-Heled N, Simons M, Neufeld G, Augustin HG.

J Biol Chem. 2008 Sep 12;283(37):25110-4. doi: 10.1074/jbc.C800137200. Epub 2008 Jul 15.

14.

Spheroid-based engineering of a human vasculature in mice.

Alajati A, Laib AM, Weber H, Boos AM, Bartol A, Ikenberg K, Korff T, Zentgraf H, Obodozie C, Graeser R, Christian S, Finkenzeller G, Stark GB, Héroult M, Augustin HG.

Nat Methods. 2008 May;5(5):439-45. doi: 10.1038/nmeth.1198. Epub 2008 Apr 6.

PMID:
18391960
15.

Inhibition of the mitogenic, angiogenic and tumorigenic activities of pleiotrophin by a synthetic peptide corresponding to its C-thrombospondin repeat-I domain.

Hamma-Kourbali Y, Bernard-Pierrot I, Heroult M, Dalle S, Caruelle D, Milhiet PE, Fernig DG, Delbé J, Courty J.

J Cell Physiol. 2008 Jan;214(1):250-9.

PMID:
17607711
16.

Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression.

Héroult M, Schaffner F, Augustin HG.

Exp Cell Res. 2006 Mar 10;312(5):642-50. Epub 2005 Dec 5. Review.

PMID:
16330025
17.

Inflammatory triggers of lymphangiogenesis.

Mouta C, Heroult M.

Lymphat Res Biol. 2003;1(3):201-18. Review.

PMID:
15624438
18.

Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration.

Pyagay P, Heroult M, Wang Q, Lehnert W, Belden J, Liaw L, Friesel RE, Lindner V.

Circ Res. 2005 Feb 4;96(2):261-8. Epub 2004 Dec 23.

PMID:
15618538
19.

Correlation of elevated plasma levels of two structurally related growth factors, heparin affin regulatory peptide and midkine, in advanced solid tumor patients.

Soulié P, Héroult M, Bernard-Pierrot I, Caruelle D, Oglobine J, Barritault D, Courty J.

Cancer Detect Prev. 2004;28(5):319-24.

PMID:
15542254
20.

Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis.

Héroult M, Bernard-Pierrot I, Delbé J, Hamma-Kourbali Y, Katsoris P, Barritault D, Papadimitriou E, Plouet J, Courty J.

Oncogene. 2004 Mar 4;23(9):1745-53.

PMID:
15001987
21.

Heparin affin regulatory peptide in milk: its involvement in mammary gland homeostasis.

Bernard-Pierrot I, Delbé J, Heroult M, Rosty C, Soulié P, Barritault D, Milhiet PE, Courty J.

Biochem Biophys Res Commun. 2004 Jan 30;314(1):277-82.

PMID:
14715276
22.

Immunoassay for measuring the heparin-binding growth factors HARP and MK in biological fluids.

Soulié P, Héroult M, Bernard I, Kerros ME, Milhiet PE, Delbé J, Barritault D, Caruelle D, Courty J.

J Immunoassay Immunochem. 2002;23(1):33-48.

PMID:
11848100
23.

HARP induces angiogenesis in vivo and in vitro: implication of N or C terminal peptides.

Papadimitriou E, Polykratis A, Courty J, Koolwijk P, Heroult M, Katsoris P.

Biochem Biophys Res Commun. 2001 Mar 23;282(1):306-13.

PMID:
11264008
24.

Endothelial cell proliferation induced by HARP: implication of N or C terminal peptides.

Papadimitriou E, Heroult M, Courty J, Polykratis A, Stergiou C, Katsoris P.

Biochem Biophys Res Commun. 2000 Jul 21;274(1):242-8.

PMID:
10903925
25.

Glycosaminoglycans promote HARP/PTN dimerization.

Bernard-Pierrot I, Héroult M, Lemaître G, Barritault D, Courty J, Milhiet PE.

Biochem Biophys Res Commun. 1999 Dec 20;266(2):437-42.

PMID:
10600521
26.

Glycosaminoglycans differentially bind HARP and modulate its biological activity.

Vacherot F, Delbé J, Heroult M, Barritault D, Fernig DG, Courty J.

J Biol Chem. 1999 Mar 19;274(12):7741-7.

Supplemental Content

Loading ...
Support Center